Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. (NASDAQ: MDXG) is a Florida-incorporated regenerative medicine and advanced wound care company that files regular reports and disclosures with the U.S. Securities and Exchange Commission. On this page, investors can review MiMedx SEC filings, including current reports on Form 8-K that detail quarterly earnings announcements, investor presentations, and shareholder meeting results, as well as other periodic reports available through EDGAR.
Recent Form 8-K filings show MiMedx reporting quarterly financial results and furnishing earnings press releases and slide presentations under Items 2.02 and 7.01. Another 8-K describes the outcomes of the company’s annual meeting of shareholders, including director elections, advisory votes on executive compensation, ratification of the independent registered public accounting firm, and approval of amendments to the equity and cash incentive plan. These documents provide insight into MiMedx’s financial condition, governance, and shareholder decisions.
For a fuller picture of MiMedx’s business, risks, and accounting policies, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible via the SEC’s EDGAR system. Those filings contain detailed discussions of the company’s advanced wound care and placental tissue–based product portfolio, risk factors, legal and regulatory matters, and management’s analysis of operations.
Stock Titan’s SEC filings page is designed to surface MiMedx filings as they are posted to EDGAR and to pair them with AI-generated summaries. These summaries can help explain complex sections of lengthy documents, highlight key items such as revenue trends, legal disclosures, or shareholder votes, and make it easier to locate information on topics like reimbursement risk, litigation with former employees, or regulatory interactions. Users can also review insider and governance-related disclosures, such as say-on-pay frequency decisions, as they appear in MiMedx’s filed materials.
MiMedx Group Chief Commercial Officer Kimberly Maersk-Moller reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 24, 2025. The insider disposed of 12,034 shares of Common Stock at a price of $5.96 per share through a tax withholding transaction (Code F).
Key Transaction Details:
- The shares were withheld for payment of tax liability upon vesting of restricted stock units
- Following the transaction, Maersk-Moller directly owns 295,282 shares of Common Stock
- The transaction was executed under a Form 4 filing obligation pursuant to Section 16(a) of the Securities Exchange Act
This routine tax-related share withholding suggests the vesting of previously awarded restricted stock units, rather than an open market sale decision by the insider.
MiMedx Group Director Todd Newton received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing his direct beneficial ownership to 412,771 shares.
Key details of the transaction:
- The grant is exempt under Rule 16b-3 as part of non-employee director compensation
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Transaction was filed via Form 4 on June 28, 2025
- Filing was signed by William F. Hulse as attorney-in-fact
This routine compensation grant reflects standard board member equity incentives and demonstrates continued alignment between director and shareholder interests.
MiMedx Group Director M. Kathleen Behrens received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing her total direct holdings to 212,771 shares.
Key details of the transaction:
- The grant is part of non-employee director compensation
- Transaction is exempt under Rule 16b-3
- Shares will vest at the earlier of 12 months or the next annual shareholder meeting
- Form 4 was filed by William F. Hulse as attorney-in-fact
This routine compensation grant demonstrates continued alignment between director and shareholder interests through equity-based compensation. The transaction represents approximately 13.4% increase in the director's direct holdings in the company.
MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.
The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:
- 12 months from grant date
- The next annual meeting of shareholders
The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.
MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share. This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.
Following the transaction, Hawkins now beneficially owns a total of 204,018 shares directly. The restricted stock grant will vest upon the earlier of 12 months or the next annual meeting of shareholders.
Key Transaction Details:
- Transaction Type: Acquisition (Form 4)
- Stock Type: Common Stock
- Transaction Value: Approximately $185,100
- Ownership Form: Direct
- Filing Date: June 28, 2025
MiMedx Group director Cato T. Laurencin acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing their total direct holdings to 181,923 shares.
The transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. Key details about the grant:
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Transaction was filed as a Form 4 pursuant to Section 16(a) of Securities Exchange Act
- The acquisition was reported as a direct ownership transaction
This insider transaction indicates ongoing compensation practices for board members and alignment with shareholder interests through equity-based compensation.
MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Olson's direct ownership increased to 57,597 shares.
Key details of the grant:
- Transaction was filed as an exempt grant under Rule 16b-3
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Grant is part of standard non-employee director compensation
- Transaction was executed through attorney-in-fact William F. Hulse
This Form 4 filing represents routine board compensation and indicates continued alignment between director and shareholder interests through equity-based compensation.